Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment
Author:
Affiliation:
1. Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
2. Khalifa Bin Zayed Al Nahyan Institute of Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Abstract
Publisher
Future Medicine Ltd
Subject
Pharmacology,Genetics,Molecular Medicine
Link
https://www.futuremedicine.com/doi/pdf/10.2217/pgs.15.174
Reference95 articles.
1. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin
2. The Cancer Genome Atlas Pan-Cancer analysis project
3. The Phosphoinositide 3-Kinase Pathway
4. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers
5. Phosphoinositide 3-kinase in immunological systems
Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The Role of PIK3R1 in Metabolic Function and Insulin Sensitivity;International Journal of Molecular Sciences;2023-08-11
2. The WW domain of IQGAP1 binds directly to the p110α catalytic subunit of PI 3-kinase;Biochemical Journal;2023-05-26
3. PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy;Scientific Reports;2023-03-18
4. Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy;Cancers;2023-01-23
5. Anti-cervical cancer effects of Compound Yangshe granule through the PI3K/AKT pathway based on network pharmacology;Journal of Ethnopharmacology;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3